ComboMATCH Screening Trial
Phase 2
2,900
about 7.2 years
All ages
476 sites in AK, AL, AR +41
What this study is about
This trial is testing a new way to treat cancer by matching it to the patient's unique genetic makeup. The goal of this screening trial is to identify patients who might benefit from targeted therapies based on their tumor's specific genetic mutations. It aims to find treatments that could control tumors and help doctors plan better treatment for people with locally advanced or advanced solid tumors.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Panitumumab
- 2.Take Alpelisib
- 3.Take Binimetinib
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
alpelisib, binimetinib, fluorouracil (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), fulvestrant, Antidotes, Deterrents, and Toxicologic Agents (Enzyme Interactions), Antineoplastic Agent [TC] (Kinase Inhibitors), Antineoplastic Agent [TC] (Bcr-Abl Tyrosine Kinase Inhibitors), olaparib
oral (Oral Tablet), oral (Oral Capsule), injection, injection (Injection), oral, intravenous
biopsy, diagnostic, imaging
Oncology